Related Experiment Video

Updated: May 3, 2026

A TIRF Microscopy Technique for Real-time, Simultaneous Imaging of the TCR and its Associated Signaling Proteins
16:10

A TIRF Microscopy Technique for Real-time, Simultaneous Imaging of the TCR and its Associated Signaling Proteins

Published on: March 22, 2012

25.3K

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants

J Trebing1, M El-Mesery2, V Schäfer1

  • 1Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Röntgenring 11, Würzburg, Germany.

Cell Death & Disease
|February 1, 2014
PubMed

Insights

Researchers developed novel fusion proteins targeting CD70-expressing tumors. These proteins combine tumor cell death induction with inhibition of CD70-CD27 interactions, offering a promising strategy for cancer therapy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • CD70-expressing tumors present a therapeutic target.
  • CD70 antibodies can inhibit CD27 stimulation.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis.

Purpose of the Study:

  • To create fusion proteins combining CD70 antibody targeting with TRAIL-mediated apoptosis.
  • To evaluate the efficacy of these fusion proteins in targeting CD70-expressing tumors.
  • To develop ADCC-independent cell death-inducing agents.

Main Methods:

  • Constructed fusion proteins of single-chain variable fragment (scFv) anti-CD70 antibody (lαhCD70) with TNC-TRAIL.
  • Investigated fusion protein binding to CD70 and apoptosis induction.
  • Introduced mutations into TRAIL to confer TRAIL receptor specificity.

Main Results:

  • Fusion protein scFv:lαhCD70-TNC-TRAIL demonstrated enhanced apoptosis induction upon CD70 binding.
  • The fusion protein effectively inhibited CD70-CD27 interactions.
  • Engineered fusion proteins exhibited CD70-restricted, TRAIL death receptor-specific activity.

Conclusions:

  • Fusion proteins of anti-CD70 scFv and TRAIL are effective in targeting CD70-expressing tumors.
  • These novel agents induce apoptosis and block CD70-CD27 signaling.
  • Receptor-specific TRAIL fusion proteins offer targeted cancer therapy potential.

More Related Videos

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

1.1K
Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs11:21

Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs

Published on: September 10, 2017

9.1K

Related Concept Videos

Conservative Site-specific Recombination and Phase Variation02:53

Conservative Site-specific Recombination and Phase Variation

Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
5.7K